Lv3
290 积分 2021-08-25 加入
High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas
9小时前
待确认
ErbB3 mRNA Expression Correlated with Specific Clinicopathologic Features of Japanese Lung Cancers
17天前
已完结
Natural killer cell therapies
19天前
已完结
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial
25天前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
2个月前
已完结
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
3个月前
已完结
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
4个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
4个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
4个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
